Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Gastroesophageal Reflux DiseaseErosive Esophagitis
Interventions
DRUG

Dexlansoprazole

Dexlansoprazole capsules

DRUG

Dexlansoprazole

Dexlansoprazole capsules

DRUG

Placebo

Dexlansoprazole placebo-matching capsules

Trial Locations (60)

Unknown

Huntsville

Mobile

Phoenix

Tucson

Anaheim

Los Angeles

San Francsco

Centennial

Thornton

Chicago

Park Ridge

Indianapolis

Louisville

Boston

Flint

Plymouth

Jackson

Kansas City

Mays Landing

Brooklyn

Toledo

Youngstown

Greenville

Kingsport

Fort Worth

Houston

Laredo

San Antonio

Ogden

Salt Lake City

Fairfax

Norfolk

Brussels

Passo Fundo

Porto Alegre

Santo André

São José do Rio Preto

Debrecen

Győr

Miskolc

Nyíregyháza

Pécs

Bari

Messina

Roma

Mexico City

Monterrey

Culiacán

Bydgoszcz

Krakow

Rzeszów

Szczecin

Torun

Warsaw

Wroclaw

Amadora

Braga

Coimbra

Lisbon

Porto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT01642615 - Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents | Biotech Hunter | Biotech Hunter